Market Cap 69.50M
Revenue (ttm) 0.00
Net Income (ttm) -9.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 11,600
Avg Vol 14,354
Day's Range N/A - N/A
Shares Out 18.29M
Stochastic %K 98%
Beta 0.59
Analysts Strong Sell
Price Target $23.00

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 39 02 26434681
Address:
Via Olgettina No. 58, Milan, Italy
TradingLaboratory
TradingLaboratory Jul. 5 at 1:38 AM
$GNTA Nice brain tumor follow up news last week
0 · Reply
HaltTradeAlert
HaltTradeAlert Jul. 2 at 4:24 PM
$GNTA Halt Time: 12:22:01 Issue Symbol: GNTA Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
UgoGreg
UgoGreg Jul. 2 at 1:33 PM
$GNTA https://youtu.be/yMQWw3upID8
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:08 PM
$GNTA (-16.4% pre) Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals https://ooc.bz/l/69130
0 · Reply
DonCorleone77
DonCorleone77 Jul. 1 at 10:35 AM
$GNTA Genenta Science announces follow-up observations in glioblastoma study Genenta Science announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme study, with 25 patients receiving Temferon. Two patients have been enrolled in the TEM-LT long-term follow-up study, surviving three years from the time of 1st surgery. One of these long-term survivors has not experienced disease progression following Temferon administration and has not required any second-line therapies. The other showed initial signs of disease progression that subsequently stabilized without additional therapeutic intervention. Both these cases suggest possible Temferon-mediated control of disease progression, which warrants further investigation in larger studies. As of the April data cutoff, the survival rate at two years in the GBM trial for unmethylated MGMT patients remained consistent at 29% with median overall survival holding steady at 17 months. In historical cohorts, uMGMT patients receiving standard of care have shown a two-year survival rate of approximately 14% and a median overall survival of 13 to 15 months. In parallel, the TEM-GU Phase 1 study-designed to enroll 12 patients with genitourinary tumors-has begun recruitment. In this trial, Temferon is administered at a fixed dose of 4M genetically modified cells per kilogram of body weight-a level previously shown to be safe and well tolerated in the TEM-GBM dose-ranging study. Genenta aims to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end. The study is designed to evaluate Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors to assess the potential for immunologic synergy in this patient population. Further clinical updates will be shared once sufficient patient experience has been gained to support meaningful interpretation. Temferon's mechanism of action is based on the reprogramming of the tumor microenvironment, which promotes the activation and durability of adaptive immune responses. A scientific manuscript demonstrating Temferon's potential to enhance and prolong the durability of CAR-T activity in preclinical murine models of solid tumors has been accepted for publication in Science Translational Medicine.
1 · Reply
Silen8222
Silen8222 Jul. 1 at 10:27 AM
$BGLC booked $GNTA great news📈
0 · Reply
siriius
siriius Jul. 1 at 10:00 AM
$GNTA why is there such little movement?
0 · Reply
siriius
siriius Jul. 1 at 9:28 AM
0 · Reply
DARKP00L
DARKP00L Jul. 1 at 9:16 AM
$GNTA 05:15 on Jul. 01 2025 Genenta Reports Emerging Survival Signals In GBM Study; 2-Year Survival Doubles Vs Historical Data; No New Safety Concerns With Temferon #tradeideas
0 · Reply
Meltingflame
Meltingflame Jul. 1 at 9:08 AM
$GNTA Fantastic news!
2 · Reply
Latest News on GNTA
Genenta Welcomes New Directors John L. Cantello, Lauren H.

May 6, 2024, 6:25 AM EDT - 1 year ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.


Genenta to Present at Upcoming Investor Conferences

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Genenta to Present at Upcoming Investor Conferences


Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 4:30 PM EDT - 3 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021


Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 27, 2022, 7:30 AM EDT - 3 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair


Genenta to Participate at Upcoming Investor Conferences

Feb 24, 2022, 7:30 AM EST - 3 years ago

Genenta to Participate at Upcoming Investor Conferences


Genenta Announces Pricing of Upsized Initial Public Offering

Dec 14, 2021, 10:36 PM EST - 3 years ago

Genenta Announces Pricing of Upsized Initial Public Offering


TradingLaboratory
TradingLaboratory Jul. 5 at 1:38 AM
$GNTA Nice brain tumor follow up news last week
0 · Reply
HaltTradeAlert
HaltTradeAlert Jul. 2 at 4:24 PM
$GNTA Halt Time: 12:22:01 Issue Symbol: GNTA Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
UgoGreg
UgoGreg Jul. 2 at 1:33 PM
$GNTA https://youtu.be/yMQWw3upID8
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:08 PM
$GNTA (-16.4% pre) Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals https://ooc.bz/l/69130
0 · Reply
DonCorleone77
DonCorleone77 Jul. 1 at 10:35 AM
$GNTA Genenta Science announces follow-up observations in glioblastoma study Genenta Science announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme study, with 25 patients receiving Temferon. Two patients have been enrolled in the TEM-LT long-term follow-up study, surviving three years from the time of 1st surgery. One of these long-term survivors has not experienced disease progression following Temferon administration and has not required any second-line therapies. The other showed initial signs of disease progression that subsequently stabilized without additional therapeutic intervention. Both these cases suggest possible Temferon-mediated control of disease progression, which warrants further investigation in larger studies. As of the April data cutoff, the survival rate at two years in the GBM trial for unmethylated MGMT patients remained consistent at 29% with median overall survival holding steady at 17 months. In historical cohorts, uMGMT patients receiving standard of care have shown a two-year survival rate of approximately 14% and a median overall survival of 13 to 15 months. In parallel, the TEM-GU Phase 1 study-designed to enroll 12 patients with genitourinary tumors-has begun recruitment. In this trial, Temferon is administered at a fixed dose of 4M genetically modified cells per kilogram of body weight-a level previously shown to be safe and well tolerated in the TEM-GBM dose-ranging study. Genenta aims to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end. The study is designed to evaluate Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors to assess the potential for immunologic synergy in this patient population. Further clinical updates will be shared once sufficient patient experience has been gained to support meaningful interpretation. Temferon's mechanism of action is based on the reprogramming of the tumor microenvironment, which promotes the activation and durability of adaptive immune responses. A scientific manuscript demonstrating Temferon's potential to enhance and prolong the durability of CAR-T activity in preclinical murine models of solid tumors has been accepted for publication in Science Translational Medicine.
1 · Reply
Silen8222
Silen8222 Jul. 1 at 10:27 AM
$BGLC booked $GNTA great news📈
0 · Reply
siriius
siriius Jul. 1 at 10:00 AM
$GNTA why is there such little movement?
0 · Reply
siriius
siriius Jul. 1 at 9:28 AM
0 · Reply
DARKP00L
DARKP00L Jul. 1 at 9:16 AM
$GNTA 05:15 on Jul. 01 2025 Genenta Reports Emerging Survival Signals In GBM Study; 2-Year Survival Doubles Vs Historical Data; No New Safety Concerns With Temferon #tradeideas
0 · Reply
Meltingflame
Meltingflame Jul. 1 at 9:08 AM
$GNTA Fantastic news!
2 · Reply
jqiqkqnvcsjakqnwbwb
jqiqkqnvcsjakqnwbwb Jul. 1 at 9:05 AM
$GNTA Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
0 · Reply
PenkeTrading
PenkeTrading Jun. 18 at 7:28 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Genenta Science SpA ADR. Is that bullish or bearish? $GNTA #RsiOversold #NASDAQ
0 · Reply
HaltTradeAlert
HaltTradeAlert May. 30 at 5:51 PM
$GNTA Halt Time: 13:48:45 Issue Symbol: GNTA Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
Armonica423
Armonica423 May. 11 at 1:24 AM
$GNTA big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
newsfile_corp
newsfile_corp May. 8 at 11:02 AM
https://nfne.ws/250990 $GNTA #InvestmentBanking #NASDAQ #Investing
0 · Reply
AlphaTuna
AlphaTuna Mar. 30 at 8:14 PM
Lowest Volume Rated General Stocks Per 3/28/2025’s Close: 1 – $DBIN 2 – $TAOIF 3 – $BARUF 4 – $CTSDF 5 – $BNET 6 – $DSNY 7 – $AMXEF 8 – $GNTA 9 – $VASO 10 – $ARESF https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-3-28-2025/
0 · Reply
mebanks
mebanks Mar. 19 at 4:48 PM
$GNTA financing terms seems favorable (at least kicking the dilution down the road): "Total Bond: €20 million ($21.9M), subscribed by ETB; Maturity: three years, with mandatory conversion at maturity (March 2028); Lock-up: two years following conversion (March 2030); ETB equity in Genenta will be capped at 29%. The maximum conversion price is $17.64 per share based on an Independent Evaluation conducted by ETB’s Advisor on Genenta." https://www.globenewswire.com/news-release/2025/03/19/3045505/0/en/Genenta-Announces-20-million-21-9M-Financing-To-Expand-Pipeline-As-Brain-Tumor-Trial-Is-Showing-Promising-Survival-Rates.html
0 · Reply
BioTuesdays
BioTuesdays Jan. 10 at 2:15 PM
Genenta strengthens pact with CDMO to enhance production $GNTA https://biotuesdays.com/2025/01/10/genenta-strengthens-pact-with-cdmo-to-enhance-production/
0 · Reply
HaltTradeAlert
HaltTradeAlert Dec. 30 at 4:04 PM
$GNTA Halt Time: 11:02:26 Issue Symbol: GNTA Reason Code: LUDP Last Price: $5.74 Volume: 66.0 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Dec. 30 at 3:53 PM
$GNTA Halt Time: 10:51:48 Issue Symbol: GNTA Reason Code: LUDP Last Price: $5.5 Volume: 39.5 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply